COMPANY
Harbin Jixianglong Biotech Co., Ltd.
Harbin Jixianglong Biotech Co., Ltd.: bulk ingredient labeler, warning letter recipient, recalling firm for Retatrutide, Tirzepatide, Semaglutide, as stated by public registers.
BULK INGREDIENT LABELER
Lists the bulk active ingredient with FDA (NDC directory).
| Retatrutide | Retatrutide, BULK INGREDIENT Regulator openFDA |
|---|---|
| Tirzepatide | Tirzepatide, BULK INGREDIENT Regulator openFDA |
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | CGMP/API/Adulterated and Misbranded Drugs, 2026-05-01 Regulator FDA warning letters |
|---|---|
| Tirzepatide | CGMP/API/Adulterated and Misbranded Drugs, 2026-05-01 Regulator FDA warning letters |
RECALLING FIRM
Recalled a product naming the peptide (FDA enforcement report).
| Semaglutide | Class II recall, Ongoing, 2026-03-11 Regulator openFDA |
|---|
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.